Company profile: Kezar Life Sciences
1.1 - Company Overview
Company description
- Provider of drug discovery and development focused on protein homeostasis, offering Zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for autoimmune diseases via immune modulation without direct immunosuppression, and KZR-261, a first-in-class Sec61 translocon inhibitor for advanced/metastatic solid tumors that blocks key secreted proteins.
Products and services
- Selective Immunoproteasome Inhibition: A therapeutic approach for autoimmune disease management that inhibits pathways driving inflammatory cytokine production and immune cell activity to achieve immune modulation without direct immunosuppression
- Zetomipzomib (KZR-616): A selective immunoproteasome inhibitor engineered to treat autoimmune diseases, modulating immune pathways to reduce inflammatory cytokine production and immune cell activity without direct immunosuppression
- KZR-261: A first-in-class, small molecule inhibitor targeting the Sec61 translocon for advanced/metastatic solid tumors, blocking key secreted proteins involved in cancer proliferation, metastasis, and immune evasion
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Kezar Life Sciences
Allergopharma
HQ: Germany
Website
- Description: Provider of allergen-specific immunotherapy for type 1 allergies such as hay fever and allergic asthma, offering Allergen Immunotherapy (AIT) to induce immunological tolerance, reduce symptoms, and prevent the progression of allergic diseases, along with diagnostics for IgE-mediated allergies to identify triggers for targeted treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Allergopharma company profile →
Therakos
HQ: United States
Website
- Description: Provider of extracorporeal photopheresis immune modulation therapy to enhance immunologic response. Offers the THERAKOS CELLEX Photopheresis System used with UVADEX (methoxsalen) Sterile Solution to treat skin manifestations of CTCL, plus single-use procedural kits. Provides training via THERAKOS INSTITUTE, MyTHERAKOS portal documentation, and 24/7 customer, clinical, technical and product support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Therakos company profile →
Sudo Biosciences
HQ: United States
Website
- Description: Provider of TYK2 pseudokinase domain–targeting medicines, including a brain-penetrant TYK2 inhibitor for multiple sclerosis and neurodegenerative diseases, and a topical TYK2 inhibitor for psoriasis and other immune-mediated dermatologic conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sudo Biosciences company profile →
Biotheryx
HQ: United States
Website
- Description: Provider of clinical-stage protein degrader therapies, including the PRODEGY platform for targeted protein degradation; PHM molecular glues that use the body’s protein disposal system to selectively degrade disease-causing proteins; BTX-A51, an oral multi-kinase inhibitor for relapsed/refractory AML and high-risk MDS; and a pipeline of first-in-class molecular glue and bifunctional degraders for oncology and inflammatory disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biotheryx company profile →
Ception Therapeutics
HQ: United States
Website
- Description: Provider of payroll management services, delivering customizable payroll solutions and advanced software for seamless, timely processing; comprehensive administration covering tax filings and employee deductions; payroll compliance with the latest laws and regulations; and consulting on best practices and audit assistance, allowing businesses to focus on growth.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ception Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Kezar Life Sciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Kezar Life Sciences
2.2 - Growth funds investing in similar companies to Kezar Life Sciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Kezar Life Sciences
4.2 - Public trading comparable groups for Kezar Life Sciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →